Type
. Host-derived oxidized phospholipids and HDL regulate innate immunity in human leprosy. The Journal of clinical investigation. 2008;118(8):2917-28.
Type
. [Leprosy: can the war be won?]. Medecine tropicale : revue du Corps de sante colonial. 2008;68(2):109.
Type
. Endocrine dysfunction in leprosy. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology. 2009;28(1):1-7.
Type
. How to prevent immunological reactions in leprosy patients and interrupt transmission of Mycobacterium leprae to healthy subjects: two hypotheses. Medical hypotheses. 2008;71(4):551-63.
Type
. Detection of viable Mycobacterium leprae in soil samples: insights into possible sources of transmission of leprosy. Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases. 2008;8(5):627-31.
Type
. ErbB2: nonimmune genetic key to leprosy. Indian journal of dermatology, venereology and leprology. 2008;74(3):272-3; author reply 273-4.
Type
. Type 1 lepra reaction presenting as immune reconstitution inflammatory syndrome. Indian journal of dermatology, venereology and leprology. 2008;74(3):265-6.
Type
. Type I reaction of Hansen's disease with exposure to adalimumab: a case report. Arthritis and rheumatism. 2008;59(7):1040-3.
Type
. Powerful bactericidal activity of moxifloxacin in human leprosy. Antimicrobial agents and chemotherapy [Internet]. 2008;52(9):3113-7. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2533472/pdf/1162-07.pdf
Type
. [Do cows get leprosy?]. Le journal des medecines cuneiformes. 2007;(10):42-4.